FDA Dermatologic & Ophthalmic Drugs Advisory Committee will meet Aug. 17 to discuss NDA 50-777 for tacrolimus ointment for short and long term treatment of signs and symptoms of atopic dermatitis. The committee will also consider Roche's Accutane for severe recalcitrant nodular acne in the afternoon of Aug. 17 and on Aug. 18. The meeting will begin both days at 8:30 a.m. at the Hilton in Gaithersburg, Md
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth